Incyte and Genesis have entered a strategic partnership for the research, discovery and development of new small-molecule ...

Incyte Corp. closed 14.97% short of its 52-week high of $83.95, which the company reached on November 8th.

Incyte and Genesis Therapeutics have agreed to discover and optimize at least two initial small molecule compounds through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS).

Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, ...

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Vontobel Holding Ltd. reduced its stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 23.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 9,467 shares of ...

Artificial intelligence (AI) technology developer Genesis Therapeutics Inc. has brought in another larger partner to go on a search for the right therapeutic small molecules. The company is getting an ...

Shares of Incyte Corp. INCY shed 1.56% to $70.16 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.24% to 6,144.15 and the ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

This unique rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up ...